---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-010640"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:32:35.509854+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aclaris Q2 net loss widens to $15.4M; advances ATI-2138, bosakitug, ATI-052 trials

## Summary
- Net loss $15.4M vs $11.0M YoY; revenue $1.8M, down 36% due to prior royalty sale.
- Cash, equivalents & securities $180.9M; runway into H2 2028 without new financing.
- Phase 2a ATI-2138 met primary/key secondary endpoints; confirms tolerability in moderate-to-severe AD.
- Phase 2 trial of bosakitug (anti-TSLP mAb) in AD dosing; top line expected H2 2026.
- Roland Kolbeck appointed CSO replacing Joe Monahan (planned retirement through Q1 2026).

## SEC filing metadata
- accession: 0001558370-25-010640
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000155837025010640/0001558370-25-010640-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000155837025010640/acrs-20250807x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-010640
- JSON: https://secwatch.observer/filing/0001558370-25-010640.json
- Plain text: https://secwatch.observer/filing/0001558370-25-010640.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.